Article thumbnail

Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs

By Bong-Seop Lee, Chi Woo Yoon, Arsen Osipov, Nuriel Moghavem, Daniel Nwachokor, Rina Amatya, Rebekah Na, Joe L. Pantoja, Michael D. Pham, Keith L. Black and John S. Yu


We demonstrated that hydrophobic derivatives of the nonsteroidal anti-inflammatory drug (NSAID)flufenamic acid (FA), can be formed into stable nanometer-sized prodrugs (nanoprodrugs) that inhibit the growth of glioma cells, suggesting their potential application as anticancer agent. We synthesized highly hydrophobic monomeric and dimeric prodrugs of FA via esterification and prepared nanoprodrugs using spontaneous emulsification mechanism. The nanoprodrugs were in the size range of 120 to 140 nm and physicochemically stable upon long-term storage as aqueous suspension, which is attributed to the strong hydrophobic interaction between prodrug molecules. Importantly, despite the highly hydrophobic nature and water insolubility, nanoprodrugs could be readily activated into the parent drug by porcine liver esterase, presenting a potential new strategy for novel NSAID prodrug design. The nanoprodrug inhibited the growth of U87-MG glioma cells with IC50 of 20 μM, whereas FA showed IC50 of 100 μM, suggesting that more efficient drug delivery was achieved with nanoprodrugs

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). a n dE .E .K n a u s ,“ O 2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies,”
  2. Adverse Reactions to Drug Formulation Agents,MarcelDekker,New York,NY,USA,1989.
  3. (2001). Anti-inflammatories inhibit cancer growth—but how?”
  4. (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of nonselective
  5. (2004). B a s l e r ,G .A .P i a z z a ,B .D j a v a ne ta l . ,“ N o n s t e r o i d a la n t i -inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention,”
  6. (2009). B.S.Lee,X.Y uan,Q.X uetal.,“Stimuli-responsiveantioxidant nanoprodrugs of NSAIDs,”
  7. (2008). C h u a n g ,A .K a r d o s h
  8. Chemoprevention strategies using NSAIDs and COX-2 inhibitors,”
  9. (2000). COX-2 and colon cancer: potential targets for chemoprevention,”
  10. (2004). COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer,”
  11. (2010). Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates,”
  12. (1999). Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy,”
  13. (2001). Cyclooxygenase inhibitors— current status and future prospects,”
  14. (2001). Cyclooxygenase-2: a novel target for cancer chemotherapy?” J o u r n a lo fC a n c e rR e s e a r c ha n dC l i n i c a lO n c o l o g y ,
  15. Development of COX inhibitors in cancer prevention and therapy,”
  16. (2002). Drug Safety Evaluation, chapter 13.8,
  17. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention,”
  18. (2003). Free radical scavengingefficiencyofNano-Sein vitro,”
  19. (2003). Furtm¨ u l l e r ,a n dC .O b i n g e r ,“ R e d o xp r o p e r -ties of myeloperoxidase,”
  20. (2001). G u p t aa n dR .N .D u B o i s ,“ C o l o r e c t a lc a n c e rp r e v e n t i o n and treatment by inhibition of cyclooxygenase-2,”
  21. (2003). Gastrointestinal effects of nonsteroidal antiinflammatory drugs,”
  22. H a m m e r s ,G .J .M e u r s ,a n dC .L .d eL i g n y ,“ C o r r e l a -tions between liquid chromatographic capacity ratio data on lichrosorb RP-18 and partition coefficients in the octanolwater system,”
  23. (1995). i a n g
  24. (2001). In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac,”
  25. (1997). Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from
  26. (2007). Inhibition of the myeloperoxidase chlorinating activity by nonsteroidal anti-inflammatory drugs: flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid,”
  27. (2000). l a b u n d e ,H .M .P e t r a s s i ,V .B .O z a ,P .R a m a n
  28. (2010). L e e ,X .Y u a n ,Q .X ue ta l . ,“ N a n o p r o d r u g so fN S A I D s inhibit the growth of U87-MG glioma cells,”
  29. (1997). l e y ,R .M o r e i r a ,T .C a l h e i r o s ,a n dE .M e n d e s ,“ A c y -l o x y m e t h y la sad r u gp r o t e c t i n gg r o u p :p a r t4 .T h eh y d r o l y s i s of tertiary amidomethyl-ester prodrugs of carboxylic acid agents,”
  30. (2000). Molecular pathology of cyclooxygenase-2 in neoplasia,”
  31. (1989). Nanocapsule formation by interfacial polymer depositionfollowingsolventdisplacement,”International
  32. (2004). Nanoemulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation,”
  33. (1991). Preparation and purification of polyisohexylcyanoacrylate nanocapsules,”
  34. (1999). R e d d e n ,R .L .M e l a n s o n ,J .A .E .D o u g l a s ,a n dA .J .D i c k , “Acyloxymethyl acidic drug derivatives: in vitro hydrolytic reactivity,”
  35. Relationships between hydrophobic (lipophilic) properties of bases and their retention in reversed-phase liquid chromatography using aqueous methanol mobile phases,”
  36. (2007). S i s k o u ,E .A .R e k k a ,A .P .K o u r o u n a k i s ,M .C .C h r y s s e l i s
  37. (1993). Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen,”
  38. (2006). Synthesis and stability of two indomethacin prodrugs,” Bioorganic andMedicinalChemistryLetters,
  39. (2008). The role of cerium redox state in the SOD mimetic activity of nanoceria,”
  40. (2003). The role of cyclooxygenase2 inhibition for the prevention and treatment of prostate carcinoma,”ClinicalProstate
  41. (2000). Two-electron reduction and one-electron oxidation of organic hydroperoxides by human myeloperoxidase,”
  42. (2009). Wright,and J.Smith, “Applicationsofnanoparticletrackinganalysisinnanoparticle research: a mini review,”